Duopharma revenue forecast to rise by next year

RHB Research said the company is likely to chart steady revenue growth in 2024 post-finalisation of the APPL tender.

PETALING JAYA: Despite the key risks of lower-than-expected sales volumes and depreciation of the ringgit against the US dollar, Duopharma Biotech Bhd is on a strong footing to rake in steady revenue growth by next year.

The attributing factors which would support the pharmaceutical company’s revenue stream include the Approved Product Purchase List (APPL) tender and higher healthcare budget allocations for next year.